Skip to main content
Premium Trial:

Request an Annual Quote

Juergen Schwiezer, Severin Schwan , Frank Humer, Shaf Yousaf, Mark Stevenson, Peter Dansky, Arthur Holden, George Church, Anthony Sinskey, Lee Hood, Doug Lauffenberger, David Barker, Michael Dyson, James Sherley

Premium
Jürgen Schwiezer will become CEO of Roche Diagnostics, a division of Roche, on Jan. 1, 2008, Roche said this week. He will replace Severin Schwan, who will become CEO of the Roche group on March 4, 2008, taking over from Frank Humer.
 
Schwiezer is currently in charge of Roche Diagnostics’ operations in Europe, the Middle East, Africa, and Latin America. He joined Boehringer Mannheim in 1976, which was acquired by Roche in 1997. During his time at Boehringer and Roche, he held a number of management posts in marketing and sales. Schwiezer holds a PhD in chemistry from the University of Münster in Germany.
 
454 Life Sciences is a subsidiary of Roche Applied Science, which is a business area of Roche Diagnostics.
 

 
Shaf Yousaf has joined Applied Biosystems as president of the molecular and cell biology systems division. He comes to ABI from Sigma-Aldrich, where he was president of the research biotech business unit.
 
In July, Applied Biosystems split its molecular and cell division into two groups: MCB Systems and MCB Consumables. At the time, Mark Stevenson, president of the division, was promoted to
executive vice president of the company. Peter Dansky heads the MCB Consumables group.
 

 
Arthur Holden will leave his post as senior vice president of corporate and market development at Illumina on Oct. 18, the company said last week in a filing with the US Securities and Exchange Commission.
 
Holden is joining the Severe Adverse Events Consortium, a new pharma-backed initiative announced last week, as director. SAEC aims to find genetic markers for severe drug-related adverse events.
 
Holden formerly was chairman and CEO of First Genetic Trust. He also served as chairman of the Pharmaceutical Biomedical Research Consortium and the DMD Translational Research Consortium, and as CEO of the SNP Consortium.
 

 
George Church and Anthony Sinskey have joined the scientific advisory board of consumer genomics startup Cambridge Genomics, In Sequence has learned.
 
Church is a professor of genetics at Harvard Medical School. In 2006, Church launched the Personal Genome Project.
 
Sinskey is a professor of microbiology and health sciences and technology at the Massachusetts Institute of Technology.
 

 
George Church, Lee Hood, and Doug Lauffenberger joined the scientific advisory board of sequencing startup Complete Genomics at its inception in mid-2006, In Sequence has learned. In addition, Mark Chee joined the company’s SAB this summer.
 
Chee is CEO and CSO of Prognosys Biosciences. He is also a co-founder of Illumina and was director of genetics research at Affymetrix. In addition, Chee is on the external scientific committee of the NIH’s Cancer Genome Atlas project. He holds a PhD in molecular biology from the University of Cambridge and a BSc in biochemistry from the University of New South Wales.
 
Lauffenburger is a professor of bioengineering at the Massachusetts Institute of Technology. He also holds appointments in the department of biology and the department of chemical engineering. He holds a BS in chemical engineering from the University of Illinois, and a PhD in chemical engineering from the University of Minnesota.
 
Church is a professor of genetics at Harvard Medical School.
 
Hood is president of the Institute for Systems Biology.
 

 
David Barker has joined the scientific advisory board of GenVault, the company said last week. He is the former vice president and chief scientific officer of Illumina. In the past, he was vice president and chief science advisor at Amersham Biosciences and vice president of research and business development at Molecular Dynamics, which Amersham acquired. Barker holds a PhD in biochemistry from BrandeisUniversity and a BS in chemistry from the California Institute of Technology.
 

 
Michael Dyson has been appointed European managing director of Codon Devices, heading the company’s new European office in the UK, Codon said this week. Prior to joining the firm, he was managing director for Sequenom and director of European sales and marketing for MicroCal.
 

 
James Sherley has joined the Boston Biomedical Research Institute, the institute, located in Watertown, Mass., said last week. Sherley, who is studying adult stem cells, comes to BBRI from the Massachusetts Institute of Technology, where he was a professor. Sherley is one of the first 10 participants in George Church’s Personal Genome Project (see In Sequence 7/31/2007).
 

 
Lee Hood was inducted into the National Academy of Engineering on Sept. 30. He is president of the Institute for Systems Biology. Hood is also a member of the National Academy of Science and the Institute of Medicine of the National Academies.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.